Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50773 |
Name | paraganglioma |
Definition | A pheochromocytoma that arises in extraadrenal sympathetic ganglia. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation benign neoplasm organ system benign neoplasm endocrine organ benign neoplasm pheochromocytoma paraganglioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | 131I-MIBG | paraganglioma | not applicable | detail... |
Unknown unknown | Sunitinib | paraganglioma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00843037 | Phase II | Sunitinib | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | Active, not recruiting | CAN | 1 |
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01967576 | Phase II | Axitinib | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | Completed | USA | 0 |
NCT02302833 | Phase I | Cabozantinib | Cabozantinib for Malignant Pheochromocytoma | Recruiting | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Recruiting | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Recruiting | USA | 0 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Active, not recruiting | USA | 1 |
NCT03008369 | Phase II | Lenvatinib | Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03165721 | Phase II | Guadecitabine | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | Completed | USA | 0 |
NCT03839498 | Phase II | Axitinib | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | Recruiting | USA | 0 |
NCT04106843 | Phase II | lutetium Lu 177 dotatate | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | Withdrawn | USA | 0 |
NCT04187404 | Phase Ib/II | EO2401 + Nivolumab | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer) | Recruiting | USA | 7 |
NCT04394858 | Phase II | Olaparib + Temozolomide Temozolomide | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer | Recruiting | USA | 0 |
NCT04614766 | Phase Ib/II | 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) | Not yet recruiting | USA | 0 |